Since its establishment in 1994, the company has focused on R&D, production, sales and service of in vitro diagnostic products, and is committed to becoming a first-class enterprise in the global diagnostic industry. Since its establishment, the company has always focused on R&D, production, sales and related services of in vitro diagnostic products. The company's main products: biochemical products, immune products, molecular diagnostic products, clinical testing products, rapid testing platforms, pathological product platforms, medical laboratory automation solutions. Corporate honors: Novel coronavirus 2019-nCoV nucleic acid detection kit (fluorescence PCR method), Mike Biotech Enterprise Technology Center was recognized as “National Enterprise Technology Center”, “National Intellectual Property Demonstration Enterprise”, etc.